解整合素-金属蛋白酶12作为子(癇)前期筛查标志物的初步研究

目的 初步评价孕中期血清解整合素-金属蛋白酶12(a disintegrin and metalloprotease 12,ADAM 12)可否作为子癇前期筛查的一种标志物. 方法 通过病例-对照研究,采用初步建立的间接竞争法ELISA检测100例子癇前期患者与200例正常妊娠妇女孕14～18周血清标本中的ADAM 12水平,将其转换成MoM值后比较其有无明显差异. 结果 正常孕妇孕14～18周血清ADAM 12中位数分别为680/μg/L、738 μg/L、801 μg/L、849μg/L和900/μg/L,子癇前期患者孕14～18周血清ADAM 12中位数分别为598μg/L、664 μg/L、729/μg/L、791 μg/L和839μg/L.子癇前期组患者血清ADAM 12 LogMoM平均值-0.05242,明显低于正常孕妇组血清ADAM 12 LogMoM平均值-0.003 68(P＜0.01). 结论 子癇前期组患者孕14～18周血清ADAM 12水平明显低于正常孕妇,孕中期血清ADAM 12可能作为子癇前期筛查的一种标志物.

Preliminary study of ADAM12,a disintegrin and metalloprotease12,as a marker for preeclampsia

Objective To assess the value of ADAM 12(a disintegrin and metalloprotease 12) levels in second-trimester maternal serum as a potential marker for preeclampsia.Methods Using preliminarily developed indirect competitive ELISA,a casc-control study was performed.Serum samples were collected every week from 14 to 18 weeks of gestation from 100 women who later developed preeclampsia and 200 normal gravidas.Serum ADAM 12 levels were assayed and converted to MoM according to different gestational age and compared.Results The median levels of serum ADAM 12 from 14 to 18 weeks of gestation in normal pregnant women were 680μg/L,738μg/L,801μg/L,849μg/L and 900 μg/L respectively,and 598μg/L,664 μg/L,729μg/L,791μg/L and 839μg/L in preeclamptic women.The serum ADAM 12 levels in preeclamptic women had a mean log MoM of-0.05242,which was significantly lower than that of the normal groups(-0.00368,P＜0.01).Conclusions The maternal serum levels of ADAM 12 are significantly lower in women who later developed preeclampsia from 14 to 18 weeks of gestation compared with normal pregnancies.Thus,second trimester serum ADAM 12 may be served as a marker for preeclampsia screening.